» Articles » PMID: 24381429

Correlation of Levels of IL-6 with Tumor Burden and Receptor Status in Patients of Locally Advanced Carcinoma Breast

Overview
Specialty Biochemistry
Date 2014 Jan 2
PMID 24381429
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammatory pathways have garnered considerable interest in the recent past as an important mediator of the molecular mechanisms leading to carcinogenesis. The present study was conducted to evaluate the correlation of levels of IL-6 with tumor burden and receptor status in patients of locally advanced carcinoma breast. This prospective study was conducted by the collaborative efforts of the departments of Surgery and Biochemistry, Maulana Azad Medical College and associated Lok Nayak Hospital and GB Pant Hospitals, New Delhi. The study population comprised of 30 cases of locally advanced breast carcinoma recruited from the surgical outpatient department. The various parameters that were evaluated include detailed clinico-pathological profile and IL-6 levels. Tissue specimens received after surgeries were examined for the various characteristics indicative of tumor prognosis. Majority of the patients was in the age group of 41-50 years and was postmenopausal. The serum level of IL-6 increased as the disease progressed from T3N1M0 to T4dN2M0 (41.4 ± 31.9 vs. 164.0 ± 31.1 pg/ml respectively). There was significant correlation of IL-6 levels with lymph node involvement, tumor grade, mitotic index and adipose tissue invasion. Emerging molecular markers are being investigated for breast cancer prognosis assessment and prediction of response to chemotherapy including selection of best possible treatment modality. Our study showed that there is progressive increase in IL-6 levels as the stage of disease progresses.

Citing Articles

Expression profile of interleukin-6, 4-hydroxy-2-nonenal, and hypoxia-inducible factor 1-α in women with breast cancer and their association with clinicopathological parameters.

Yahia S, Tahari Z, Medjdoub A, Tahari F, Bessaih N, Messatfa M Contemp Oncol (Pozn). 2023; 27(1):14-21.

PMID: 37266334 PMC: 10230239. DOI: 10.5114/wo.2023.127199.


Comprehensive genomic profile of cholangiocarcinomas in China.

Tian W, Hu W, Shi X, Liu P, Ma X, Zhao W Oncol Lett. 2020; 19(4):3101-3110.

PMID: 32256810 PMC: 7074170. DOI: 10.3892/ol.2020.11429.


Digitoxin Inhibits Epithelial-to-Mesenchymal-Transition in Hereditary Castration Resistant Prostate Cancer.

Pollard B, Suckow M, Wolter W, Starr J, Eidelman O, Dalgard C Front Oncol. 2019; 9:630.

PMID: 31428571 PMC: 6687970. DOI: 10.3389/fonc.2019.00630.


Significance of Interleukin-6 in Papillary Thyroid Carcinoma.

Kobawala T, Trivedi T, Gajjar K, Patel D, Patel G, Ghosh N J Thyroid Res. 2016; 2016:6178921.

PMID: 27034885 PMC: 4808558. DOI: 10.1155/2016/6178921.


Pre-treatment effects of peripheral tumors on brain and behavior: neuroinflammatory mechanisms in humans and rodents.

Schrepf A, Lutgendorf S, Pyter L Brain Behav Immun. 2015; 49:1-17.

PMID: 25958011 PMC: 4567396. DOI: 10.1016/j.bbi.2015.04.010.

References
1.
Carter C, Allen C, Henson D . Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63(1):181-7. DOI: 10.1002/1097-0142(19890101)63:1<181::aid-cncr2820630129>3.0.co;2-h. View

2.
Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y . An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology. 2000; 59(2):166-73. DOI: 10.1159/000012155. View

3.
Kozlowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz M . Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Rocz Akad Med Bialymst. 2004; 48:82-4. View

4.
Rokavec M, Wu W, Luo J . IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell. 2012; 45(6):777-89. PMC: 3319241. DOI: 10.1016/j.molcel.2012.01.015. View

5.
Jiang X, Yang D, Elliott R, Head J . Reduction in serum IL-6 after vacination of breast cancer patients with tumour-associated antigens is related to estrogen receptor status. Cytokine. 2000; 12(5):458-65. DOI: 10.1006/cyto.1999.0591. View